TP53 and acute myeloid leukemia: Thus, it is tempting to speculate that additional patients with TP53-mutated AML, including those with additional targetable comutations, therapy-related AML, and/or relapsed/refractory AML, might respond favorably to TP-0903, although this was not tested in this trial.